Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 4 de 4
1.
Sci Rep ; 12(1): 6160, 2022 04 13.
Article En | MEDLINE | ID: mdl-35418597

Endogenous remyelination in demyelinating diseases such as multiple sclerosis is contingent upon the successful differentiation of oligodendrocyte progenitor cells (OPCs). Signaling via the Gαq-coupled muscarinic receptor (M1/3R) inhibits human OPC differentiation and impairs endogenous remyelination in experimental models. We hypothesized that calcium release following Gαq-coupled receptor (GqR) activation directly regulates human OPC (hOPC) cell fate. In this study, we show that specific GqR agonists activating muscarinic and metabotropic glutamate receptors induce characteristic oscillatory calcium release in hOPCs and that these agonists similarly block hOPC maturation in vitro. Both agonists induce calcium release from endoplasmic reticulum (ER) stores and store operated calcium entry (SOCE) likely via STIM/ORAI-based channels. siRNA mediated knockdown (KD) of obligate calcium sensors STIM1 and STIM2 decreased the magnitude of muscarinic agonist induced oscillatory calcium release and attenuated SOCE in hOPCs. In addition, STIM2 expression was necessary to maintain the frequency of calcium oscillations and STIM2 KD reduced spontaneous OPC differentiation. Furthermore, STIM2 siRNA prevented the effects of muscarinic agonist treatment on OPC differentiation suggesting that SOCE is necessary for the anti-differentiative action of muscarinic receptor-dependent signaling. Finally, using a gain-of-function approach with an optogenetic STIM lentivirus, we demonstrate that independent activation of SOCE was sufficient to significantly block hOPC differentiation and this occurred in a frequency dependent manner while increasing hOPC proliferation. These findings suggest that intracellular calcium oscillations directly regulate hOPC fate and that modulation of calcium oscillation frequency may overcome inhibitory Gαq-coupled signaling that impairs myelin repair.


Calcium Signaling , Oligodendrocyte Precursor Cells , Calcium/metabolism , Calcium Signaling/physiology , Calcium, Dietary/metabolism , Humans , Muscarinic Agonists/pharmacology , ORAI1 Protein/metabolism , Oligodendrocyte Precursor Cells/metabolism , RNA, Small Interfering/genetics , RNA, Small Interfering/metabolism , Stromal Interaction Molecule 1/genetics , Stromal Interaction Molecule 1/metabolism , Stromal Interaction Molecule 2/metabolism
2.
Nat Commun ; 12(1): 1923, 2021 03 26.
Article En | MEDLINE | ID: mdl-33772011

Chronic demyelination in the human CNS is characterized by an inhibitory microenvironment that impairs recruitment and differentiation of oligodendrocyte progenitor cells (OPCs) leading to failed remyelination and axonal atrophy. By network-based transcriptomics, we identified sulfatase 2 (Sulf2) mRNA in activated human primary OPCs. Sulf2, an extracellular endosulfatase, modulates the signaling microenvironment by editing the pattern of sulfation on heparan sulfate proteoglycans. We found that Sulf2 was increased in demyelinating lesions in multiple sclerosis and was actively secreted by human OPCs. In experimental demyelination, elevated OPC Sulf1/2 expression directly impaired progenitor recruitment and subsequent generation of oligodendrocytes thereby limiting remyelination. Sulf1/2 potentiates the inhibitory microenvironment by promoting BMP and WNT signaling in OPCs. Importantly, pharmacological sulfatase inhibition using PI-88 accelerated oligodendrocyte recruitment and remyelination by blocking OPC-expressed sulfatases. Our findings define an important inhibitory role of Sulf1/2 and highlight the potential for modulation of the heparanome in the treatment of chronic demyelinating disease.


Cell Differentiation/genetics , Cellular Microenvironment/genetics , Demyelinating Diseases/genetics , Gene Expression Profiling/methods , Oligodendrocyte Precursor Cells/metabolism , Remyelination/genetics , Animals , Axons/metabolism , Cells, Cultured , Demyelinating Diseases/metabolism , Female , Humans , Mice , Mice, Inbred BALB C , Mice, Knockout , Mice, Transgenic , Multiple Sclerosis/genetics , Multiple Sclerosis/metabolism , Oligodendrocyte Precursor Cells/cytology , Sulfatases/genetics , Sulfatases/metabolism , Sulfotransferases/genetics , Sulfotransferases/metabolism
3.
Infect Immun ; 84(4): 976-988, 2016 Apr.
Article En | MEDLINE | ID: mdl-26787720

In previous work, we identified xanthine oxidase (XO) as an important enzyme in the interaction between the host and enteropathogenic Escherichia coli(EPEC) and Shiga-toxigenic E. coli(STEC). Many of the biological effects of XO were due to the hydrogen peroxide produced by the enzyme. We wondered, however, if uric acid generated by XO also had biological effects in the gastrointestinal tract. Uric acid triggered inflammatory responses in the gut, including increased submucosal edema and release of extracellular DNA from host cells. While uric acid alone was unable to trigger a chloride secretory response in intestinal monolayers, it did potentiate the secretory response to cyclic AMP agonists. Uric acid crystals were formed in vivo in the lumen of the gut in response to EPEC and STEC infections. While trying to visualize uric acid crystals formed during EPEC and STEC infections, we noticed that uric acid crystals became enmeshed in the neutrophilic extracellular traps (NETs) produced from host cells in response to bacteria in cultured cell systems and in the intestine in vivo Uric acid levels in the gut lumen increased in response to exogenous DNA, and these increases were enhanced by the actions of DNase I. Interestingly, addition of DNase I reduced the numbers of EPEC bacteria recovered after a 20-h infection and protected against EPEC-induced histologic damage.


Escherichia coli Infections/metabolism , Uric Acid/metabolism , Animals , Cell Line , Colforsin/pharmacology , Enterohemorrhagic Escherichia coli , Gastrointestinal Hormones/pharmacology , Humans , Intestines , Natriuretic Peptides/pharmacology , Rabbits , Shiga-Toxigenic Escherichia coli , Uric Acid/pharmacology , Xanthine Oxidase/metabolism
4.
Infect Immun ; 81(4): 1129-39, 2013 Apr.
Article En | MEDLINE | ID: mdl-23340314

Xanthine oxidase (XO), also known as xanthine oxidoreductase, has long been considered an important host defense molecule in the intestine and in breastfed infants. Here, we present evidence that XO is released from and active in intestinal tissues and fluids in response to infection with enteropathogenic Escherichia coli (EPEC) and Shiga-toxigenic E. coli (STEC), also known as enterohemorrhagic E. coli (EHEC). XO is released into intestinal fluids in EPEC and STEC infection in a rabbit animal model. XO activity results in the generation of surprisingly high concentrations of uric acid in both cultured cell and animal models of infection. Hydrogen peroxide (H(2)O(2)) generated by XO activity triggered a chloride secretory response in intestinal cell monolayers within minutes but decreased transepithelial electrical resistance at 6 to 22 h. H(2)O(2) generated by XO activity was effective at killing laboratory strains of E. coli, commensal microbiotas, and anaerobes, but wild-type EPEC and STEC strains were 100 to 1,000 times more resistant to killing or growth inhibition by this pathway. Instead of killing pathogenic bacteria, physiologic concentrations of XO increased virulence by inducing the production of Shiga toxins from STEC strains. In vivo, exogenous XO plus the substrate hypoxanthine did not protect and instead worsened the outcome of STEC infection in the rabbit ligated intestinal loop model of infection. XO released during EPEC and STEC infection may serve as a virulence-inducing signal to the pathogen and not solely as a protective host defense.


Enteropathogenic Escherichia coli/pathogenicity , Escherichia coli Infections/pathology , Host-Pathogen Interactions , Shiga-Toxigenic Escherichia coli/pathogenicity , Xanthine Oxidase/metabolism , Animals , Bodily Secretions/enzymology , Cell Line , Disease Models, Animal , Enteropathogenic Escherichia coli/drug effects , Enteropathogenic Escherichia coli/immunology , Escherichia coli Infections/immunology , Escherichia coli Infections/microbiology , Humans , Hydrogen Peroxide/metabolism , Intestines/enzymology , Intestines/immunology , Rabbits , Shiga-Toxigenic Escherichia coli/drug effects , Shiga-Toxigenic Escherichia coli/immunology , Uric Acid/metabolism , Virulence/drug effects , Xanthine Oxidase/immunology
...